Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized study of GDC-0980 versus everolimus in metastatic renal cell carcinoma after VEGF-targeted therapy
2011-000493-56Phase 2Completed
- Sponsor
- Genentech
- Start
- Sep 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in renal cell carcinoma (RCC) comparing GDC-0980 with Everolimus (2 arms). Primary endpoint: Progression-free survival. Started Sep 2011; status: completed.
02
Drugs
apitolisibeverolimus
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2011-000493-56.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000493-56.